Caribou Biosciences' vispa-cel, a Phase 3-ready allogeneic CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, has a Food and Drug Administration-agreed pivotal Phase 3 trial design.

From the articleCaribou Biosciences stock plunges 40% on halt of CAR-T programs By Investing.comAlso in Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up, Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down, Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road - MedCity News, Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate, Caribou Biosciences to Evaluate Strategic Alternatives